Replimune Group, Inc. (REPL)
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
$829.59M
Mr. Philip Astley-Sparke F.S.A., FSA
206.00
Woburn, MA
Jul 20, 2018
-3.71
$-3.27
3.30
17.06
0.00%
-3.80
0.19
1.35
0.00
16.81
-30.13%
-35.52%
Similar stocks (11)
Nuvalent, Inc.
NUVL
Crinetics Pharmaceuticals, Inc.
CRNX
Keros Therapeutics, Inc.
KROS
Protagonist Therapeutics, Inc.
PTGX
Kura Oncology, Inc.
KURA
PureTech Health plc
PRTC
Nuvectis Pharma, Inc.
NVCT
Gossamer Bio, Inc.
GOSS
Aerovate Therapeutics, Inc.
AVTE
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (23)
Loncar Cancer Immunotherapy ETF
CNCR
3.54%
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
1.03%
Invesco DWA Healthcare Momentum ETF
PTH
0.778%
iShares Micro-Cap ETF
IWC
0.1747%
Direxion Daily S&P Biotech Bull 3X Shares
LABU
0.1113034445%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.083%
iShares Biotechnology ETF
IBB
0.0625%
iShares Russell 2000 Value ETF
IWN
0.05298%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.029%
iShares Russell 2000 ETF
IWM
0.02598%
ProShares Ultra Nasdaq Biotechnology
BIB
0.024971562725406543%
Dimensional U.S. Small Cap ETF
DFAS
0.02207263%
Schwab U.S. Small-Cap ETF
SCHA
0.0177040065%
Fidelity MSCI Health Care Index ETF
FHLC
0.00553722%
ALPS Medical Breakthroughs ETF
SBIO
0.0051%
ProShares Hedge Replication ETF
HDG
0.004155508509720073%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
0.00135%
Dimensional U.S. Core Equity 2 ETF
DFAC
0.00125862%
Dimensional U.S. Equity ETF
DFUS
0.0012584%
Schwab U.S. Broad Market ETF
SCHB
0.0010698284%
iShares Russell 3000 ETF
IWV
8.2e-4%
Dimensional U.S. Targeted Value ETF
DFAT
7.9614e-4%
Dimensional US Core Equity Market ETF
DFAU
5.062900000000001e-4%
Similar stocks (11)
Nuvalent, Inc.
NUVL
Crinetics Pharmaceuticals, Inc.
CRNX
Keros Therapeutics, Inc.
KROS
Protagonist Therapeutics, Inc.
PTGX
Kura Oncology, Inc.
KURA
PureTech Health plc
PRTC
Nuvectis Pharma, Inc.
NVCT
Gossamer Bio, Inc.
GOSS
Aerovate Therapeutics, Inc.
AVTE
Kronos Bio, Inc.
KRON
Lyra Therapeutics, Inc.
LYRA
ETF Exposure (23)
Loncar Cancer Immunotherapy ETF
CNCR
3.54%
Listed Funds Trust - Horizon Kinetics Medical ETF
MEDX
1.03%
Invesco DWA Healthcare Momentum ETF
PTH
0.778%
iShares Micro-Cap ETF
IWC
0.1747%
Direxion Daily S&P Biotech Bull 3X Shares
LABU
0.1113034445%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.083%
iShares Biotechnology ETF
IBB
0.0625%
iShares Russell 2000 Value ETF
IWN
0.05298%
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
0.029%
iShares Russell 2000 ETF
IWM
0.02598%
ProShares Ultra Nasdaq Biotechnology
BIB
0.024971562725406543%
Dimensional U.S. Small Cap ETF
DFAS
0.02207263%
Schwab U.S. Small-Cap ETF
SCHA
0.0177040065%
Fidelity MSCI Health Care Index ETF
FHLC
0.00553722%
ALPS Medical Breakthroughs ETF
SBIO
0.0051%
ProShares Hedge Replication ETF
HDG
0.004155508509720073%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
0.00135%
Dimensional U.S. Core Equity 2 ETF
DFAC
0.00125862%
Dimensional U.S. Equity ETF
DFUS
0.0012584%
Schwab U.S. Broad Market ETF
SCHB
0.0010698284%
iShares Russell 3000 ETF
IWV
8.2e-4%
Dimensional U.S. Targeted Value ETF
DFAT
7.9614e-4%
Dimensional US Core Equity Market ETF
DFAU
5.062900000000001e-4%